ARVN

Announcements

Nothing here yet

Daily updates

• Arvinas reported final Phase 1 ARV-102 Parkinson's data showing CNS penetration, LRRK2 degradation, and exploratory dose-related improvements in saccadic hypometria.Oct 7, 2026

FDA designations

Nothing here yet

News

• Arvinas will present novel biomarker data from the Phase 1 trial of ARV-102, a PROTAC LRRK2 degrader, at the 2026 International Congress of Parkinson's Disease and Movement DisordersOct 2, 2026
• Arvinas doses the first patient in the Phase 1/2 trial of ARV-6723, its first immuno-oncology candidateSep 28, 2026
• Patient-reported outcomes from VERITAC-2 clinical trial support clinical benefit of Vepdegestrant in patients with ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapyOct 20, 2025
• Arvinas presents late breaking, positive Phase 1 clinical data for ARV-102, a PROTAC LRRK2 degrader, at 2025 International Congress of Parkinson's Disease and Movement Disorders®Oct 6, 2025
• Arvinas to present clinical data for ARV-102, a PROTAC LRRK2 degrader, at 2025 International Congress of Parkinson's Disease and Movement Disorders®Oct 1, 2025